Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.307
Filtrar
1.
Medicine (Baltimore) ; 100(11): e25161, 2021 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-33726001

RESUMO

RATIONALE: An intravitreal dexamethasone (IV-DEX) implant is safe and effective for the treatment of macular edemas; however, the efficacy of IV-DEX implants in silicone oil (SO)-filled eyes remains controversial. There is no previous study comparing an IV-DEX implant in the same eye with and without intravitreal SO. PATIENT CONCERNS: A 72-year-old man with proliferative diabetic retinopathy, macular edema, and rhegmatogenous retinal detachment, treated with pars plana vitrectomy with SO tamponade had refractory macular edema. DIAGNOSIS: Refractory macular edema. INTERVENTION: Subtenon triamcinolone injection, intravitreal anti-vascular endothelial growth factor injection, and IV-DEX implantation were performed; this was followed by intravitreal SO removal combined with IV-DEX implantation. OUTCOMES: The macular edema did not decrease significantly with posterior subtenon triamcinolone injection, intravitreal anti-vascular endothelial growth factor injection, and IV-DEX implantation; however, the edema was relieved after SO removal and a new IV-DEX implantation. LESSONS: IV-DEX implant may be less efficacious in the treatment of macular edema in an SO-filled eye than that in a normal vitreous cavity.


Assuntos
Dexametasona/administração & dosagem , Retinopatia Diabética/tratamento farmacológico , Edema Macular/tratamento farmacológico , Descolamento Retiniano/tratamento farmacológico , Óleos de Silicone/administração & dosagem , Idoso , Remoção de Dispositivo , Implantes de Medicamento/administração & dosagem , Humanos , Injeções Intravítreas , Masculino , Triancinolona/administração & dosagem , Fatores de Crescimento do Endotélio Vascular/administração & dosagem , Vitrectomia/métodos
2.
Am J Otolaryngol ; 42(3): 102892, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33493729

RESUMO

BACKGROUND: To study the outcome of fluticasone nasal sprays in smell disorders and triamcinolone paste in taste dysfunction in a population of laboratory-confirmed SARS-CoV-2 patients as the test group. The control group will not be given any intervention and only monitoring of these symptoms will be done to compare the recovery time. METHODS: This prospective interventional study was conducted from June to Nov 2020 at, Datta Meghe University during the COVID-19 outbreak. The 120 enrolled patients were tested at days 1 and 5 after proven infection by RT-PCR test. RESULT: The mean age for all cases is 50.88 ± 15.93 years, whereas for the controls mean age is 51.2 ± 14.89. 2. Among cases 45 (75%) were males and 15 (25%) were females, among controls 43 (71.66%) were males and 17 (28.33%) were females. Among the case group, after the use of fluticasone spray in the nose and triamcinolone paste in the mouth there was a statistically significant improvement in recognizing all the odours and taste on day 5 compared to day 1. On comparing the smell and taste of cases and control group, either there is no improvement or worsening in smell or taste on day 5 in the control group. CONCLUSION: The use of fluticasone nasal spray and triamcinolone paste had immensely influenced the basic senses such as smell and taste. Our study showed that olfactory and taste function significantly improved in patients with COVID-19. For all anosmia and dysgeusia cases who received fluticasone nasal spray and triamcinolone medications the recovery of smell senses and the taste was within a week.


Assuntos
/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Disgeusia/tratamento farmacológico , Fluticasona/uso terapêutico , Triancinolona/uso terapêutico , Administração Oral , Anti-Inflamatórios/administração & dosagem , Estudos de Casos e Controles , Feminino , Fluticasona/administração & dosagem , Humanos , Índia/epidemiologia , Masculino , Pessoa de Meia-Idade , Sprays Nasais , Estudos Prospectivos , Triancinolona/administração & dosagem
3.
BMJ Case Rep ; 14(1)2021 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-33431535

RESUMO

A 27-year-old woman presented to the dermatology department with a 1-year history of multiple asymptomatic violaceous lesions on her upper and lower extremities, trunk and abdomen. The lesions were firm on palpation. She had no other associated symptoms and the rest of the examination was unremarkable. An incisional biopsy showed multiple confluent granulomas composed of histiocytes devoid of necrosis surrounded by a rim of lymphocytes extending to the subcutaneous fat consistent with the diagnosis of subcutaneous sarcoidosis. The serum ACE assay was elevated at 134 IU/L. Other blood tests including complete blood count, renal and liver function tests, serum calcium and phosphate were within normal ranges and chest X-ray was unremarkable. Complete remission was achieved with an intralesional triamcinolone injection (10 mg/mL) for a few sessions. Subcutaneous sarcoidosis is a rare variation and its diagnosis requires a high index of suspicion.


Assuntos
Sarcoidose/diagnóstico , Dermatopatias/diagnóstico , Triancinolona/administração & dosagem , Adulto , Doenças Assintomáticas/terapia , Biópsia , Diagnóstico Diferencial , Feminino , Humanos , Injeções Intralesionais , Peptidil Dipeptidase A/análise , Sarcoidose/sangue , Sarcoidose/tratamento farmacológico , Sarcoidose/patologia , Pele/patologia , Dermatopatias/sangue , Dermatopatias/tratamento farmacológico , Dermatopatias/patologia , Resultado do Tratamento
6.
Pain Physician ; 23(4S): S283-S294, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32942788

RESUMO

BACKGROUND: The suppression of hypothalamic-pituitary-adrenal (HPA) axis is a common complication associated with epidural steroid injections (ESIs). However, the effect of different doses is unknown. OBJECTIVES: The primary objective was to compare the differences in the duration of HPA suppression following treatment with different doses of ESI; triamcinolone acetate (TA) 40 mg and TA 20 mg. The secondary objectives were to compare the extent of salivary cortisol (SC) reduction, the incidence of adrenal insufficiency (AI), and the differences in a numeric rating scale (NRS) depending on the varying levels of TA dose used for ESI. STUDY DESIGN: A double-blind, parallel-group, randomized controlled trial. SETTING: Pain clinics in a university hospital. METHODS: The patients were treated with TA epidurally and divided into 2 groups (T20 and T40) depending on the dose of TA (20 mg and 40 mg). The SC concentration was measured before and after ESI to calculate the duration of HPA axis suppression, the extent of SC concentration reduction, and the SC recovery rate. Additionally, NRS and adrenocorticotropic hormone stimulation tests were used. RESULTS: Thirty patients were analyzed. The T40 group showed longer HPA suppression (19.7 ± 3.1 days) compared with that of the T20 group (8.0 ± 2.4 days). The recovery rate of the T40 group was lower than that of the T20 group (P < 0.015). However, there was no difference in the extent of reduction in SC concentration after ESI, the occurrence of AI, and pain reduction. LIMITATIONS: There were selection bias and no placebo control. CONCLUSIONS: Although the difference in pain relief according to the ESI dose is not significant, the HPA suppression is prolonged with a higher dose than a lower dose, and the recovery is slower. Therefore, the time interval between consecutive ESIs should be adjusted depending on the steroid dose to ameliorate the adverse effects of steroids.


Assuntos
Anti-Inflamatórios/administração & dosagem , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Triancinolona/administração & dosagem , Insuficiência Adrenal/induzido quimicamente , Adulto , Anti-Inflamatórios/efeitos adversos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Hidrocortisona/análise , Masculino , Pessoa de Meia-Idade , Dor/tratamento farmacológico , Dor/etiologia , Saliva/química , Doenças da Coluna Vertebral/complicações , Doenças da Coluna Vertebral/tratamento farmacológico , Triancinolona/efeitos adversos
7.
Pain Physician ; 23(4): 405-412, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32709175

RESUMO

BACKGROUND: This study describes the use of transversus abdominis plane (TAP) blocks to treat and manage chronic abdominal pain (CAP) in patients who have exhausted other treatment options. Typically, this is a procedure prescribed for treating acute abdominal pain following abdominal surgery. Here we evaluate the use of TAP blocks for longer relief from CAP. OBJECTIVES: To assess the efficacy of TAP blocks for pain control in patients with CAP. STUDY DESIGN: This was a retrospective chart review and analysis of TAP blocks performed over 5 years. This project qualified for institutional review board exemption. SETTING: This study was completed at an academic institution. METHODS: We reviewed the charts of 92 patients who received TAP blocks for CAP after previous treatment was ineffective. Some patients underwent multiple TAP blocks, with a total of 163 individual procedures identified. For most blocks, a solution of 0.25% bupivacaine and triamcinolone was injected into the TAP. Efficacy of the injection was measured using pain scores, percent improvement, and duration of relief from pain. RESULTS: TAP blocks were associated with a statistically significant (P <= 0.05) improvement in abdominal pain scores in 81.9% of procedures. Improvement was 50.3% ± 39.0% with an average duration of 108 days after procedures with ongoing pain relief at time of follow-up were removed. There was a significant reduction in emergency department visits for abdominal pain before and after the procedure (P <= 0.05). LIMITATIONS: This was a retrospective chart review with lack of a control group. CONCLUSIONS: TAP blocks can be extrapolated for treating abdominal pain beyond acute settings. TAP injections can be considered as a treatment option for patients with somatosensory CAP refractory to other forms of pain management. KEY WORDS: Abdominal pain, transversus abdominis plane block, chronic pain, chronic abdominal pain, pain management, somatosensory pain, transversus abdominis plane, steroid injection.


Assuntos
Músculos Abdominais/efeitos dos fármacos , Dor Abdominal/terapia , Dor Crônica/terapia , Bloqueio Nervoso/métodos , Manejo da Dor/métodos , Músculos Abdominais/inervação , Dor Abdominal/diagnóstico , Adulto , Anestésicos Locais/administração & dosagem , Bupivacaína/administração & dosagem , Dor Crônica/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Triancinolona/administração & dosagem
8.
Pain Physician ; 23(4): E417-E424, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32709188

RESUMO

BACKGROUND: Epidural steroid injection (ESI) is a common practice for pain treatment since 1953. In 2014, the FDA issued a warning about ESI. Studies have focused on the effect of the particle size and their ability to generate harmful aggregates. Although steroid aggregates provide longer times for reabsorption, therefore a longer anti-inflammatory effect, they are potentially harmful to the central nervous system via embolic mechanisms.Previous studies have established that steroidal aggregates with asizes over 100 mu m are potentially able to occlude blood vessels. Studies by Tiso et al and Benzon et al addressed the role of steroids on CNS adverse events, with similar outcomes. The main difference was on the role of aggregates with a size over 100 mu m, which Benzon et al. attributed to the ability of certain steroid preparations to rapidly precipitate and form large aggregates. OBJECTIVES: Studying the effect of the time elapsed between mixing the steroid preparation and injection on the number and size of aggregates with sizes above 100 mu m. STUDY DESIGN: Original study in basic science. SETTING: Basic scienceMETHODS: Steroids evaluated are commonly used in Spain for ESI: betamethasone, triamcinolone, and dexamethasone. The size and number of the aggregates was determined for undiluted commercial steroid preparations in the usual amount for a single and double dosage used for ESI.Samples were examined with a Leica TCS-SP2 microscope at the first, the fifth and the 30th minute after shaking the preparations. Aggregates observed in the different preparations were manually counted and grouped in the following size range: 0-20, 20-50, 50-100, 100-300, 300-500 and > 500 mu m.Statistical analysis was carried out using the R software. Nonparametric techniques were used in the comparison of aggregate size. Global comparison of the groups using the Kruskal-Wallis test and post-hoc comparisons using the Wilcoxon test, adjusting P-values by the Holm method for multiple comparisonsRESULTS: Aggregates present in triamcinolone and betamethasone samples were statistically larger than in dexamethasone samples. Triamcinolone suspensions produced significantly larger aggregates than betamethasone five minutes after mixing. Triamcinolone preparations produced greater particle aggregates (> 500 mu m), which were not present in dexamethasone and betamethasone preparations. LIMITATIONS: Study how the human internal factors like blood elements and spinal fluid could interact with steroids and influence the size of the aggregates formed. CONCLUSIONS: This study demonstrates that the size of the particles injected depends on the type of steroid and the time allowed between mixing and injecting. The results demonstrate that waiting longer than 5 minutes between mixing and injecting can predispose the formation of potentially harmful aggregates in triamcinolone and betamethasone samples. The presence of greater particle aggregates (> 500 mu m) may occlude some important vessels and arteries with serious adverse results. Vigorous shaking of the injectable could prevent such events. KEY WORDS: Epidural steroid injection, triamcinolone, betamethasone, dexamethasone, steroid aggregates.


Assuntos
Tamanho da Partícula , Esteroides/administração & dosagem , Esteroides/química , Betametasona/administração & dosagem , Betametasona/química , Dexametasona/administração & dosagem , Dexametasona/química , Glucocorticoides/administração & dosagem , Glucocorticoides/química , Humanos , Injeções Epidurais/métodos , Microscopia/métodos , Triancinolona/administração & dosagem , Triancinolona/química
9.
J Surg Res ; 254: 300-305, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32497924

RESUMO

BACKGROUND: Granulomatous mastitis (GM) is a rare entity of benign origin. Multiple treatment strategies, including surgical procedures, can have sequelae of recurrence, nonhealing wounds, and protracted pain. Even after GM is diagnosed, the best management strategy remains controversial. We sought to evaluate intralesional steroid injection as a potential treatment for GM. MATERIALS AND METHODS: Electronic medical records from 2003 to 2017 of patients diagnosed with benign breast lesions were retrospectively reviewed. Patients with pathologically confirmed GM were identified. All treatment methods were documented, which included observation, oral steroids, methotrexate, steroid injection, and surgical excision. Primary outcome was time to resolution. Effectiveness was based on relief of symptoms along with duration of symptoms from initial time of diagnosis to full relief. Analysis of variance was used to compare outcomes between groups. RESULTS: Of the 49 patients with confirmed GM diagnoses, 57% had observation only, 24% had steroid injection, and 19% had surgical resection. The average time to resolution differed significantly among the three groups (11.5 mo from the start of observation, 2.0 mo from the time of steroid injection, and 0.5 mo from the time of surgical excision, P < 0.001). CONCLUSIONS: Intralesional steroid injection is an effective treatment of GM. Selective management is appropriate for patients with GM, and surgical resection is not required for most patients.


Assuntos
Glucocorticoides/administração & dosagem , Mastite Granulomatosa/tratamento farmacológico , Triancinolona/administração & dosagem , Adulto , Feminino , Humanos , Injeções , Pessoa de Meia-Idade , Estudos Retrospectivos
10.
J Vasc Interv Radiol ; 31(6): 1005-1009.e1, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32376174

RESUMO

Superior hypogastric nerve block (SHNB) decreases pain and use of narcotic pain medication following uterine artery embolization (UAE). The purpose of this retrospective study was to evaluate the effect of the addition of a corticosteroid (triamcinolone) to SHNB on analgesia following UAE. Records of 16 patients were reviewed for when pain occurred or acutely worsened after the procedure. No major complications were identified. Patients reported that pain began or worsened an average of 33.8 hours after the procedure, when their average pain increased from 0.6/10 to 5.9/10 (P < .001). This suggests that addition of triamcinolone to SHNB could result in prolonged analgesia following UAE.


Assuntos
Analgésicos/administração & dosagem , Glucocorticoides/administração & dosagem , Plexo Hipogástrico , Bloqueio Nervoso , Manejo da Dor/métodos , Dor/prevenção & controle , Triancinolona/administração & dosagem , Embolização da Artéria Uterina/efeitos adversos , Adulto , Analgésicos/efeitos adversos , Feminino , Glucocorticoides/efeitos adversos , Humanos , Pessoa de Meia-Idade , Bloqueio Nervoso/efeitos adversos , Dor/diagnóstico , Dor/etiologia , Manejo da Dor/efeitos adversos , Medição da Dor , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Triancinolona/efeitos adversos
12.
Drug Ther Bull ; 58(4): 57-59, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32051146

RESUMO

Topics for DTB review articles are selected by DTB's editorial board to provide concise overviews of medicines and other treatments to help patients get the best care. Articles include a summary of key points and a brief overview for patients.


Assuntos
Glucocorticoides/administração & dosagem , Rinite Alérgica Sazonal/tratamento farmacológico , Triancinolona/administração & dosagem , Preparações de Ação Retardada , Glucocorticoides/efeitos adversos , Humanos , Injeções Intramusculares , Resultado do Tratamento , Triancinolona/efeitos adversos
13.
J Allergy Clin Immunol ; 145(1): 127-139, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31604088

RESUMO

BACKGROUND: Tools for quantification of asthma severity are limited. OBJECTIVE: We sought to develop a continuous measure of asthma severity, the Asthma Severity Scoring System (ASSESS), for adolescents and adults, incorporating domains of asthma control, lung function, medications, and exacerbations. METHODS: Baseline and 36-month longitudinal data from participants in phase 3 of the Severe Asthma Research Program (NCT01606826) were used. Scale properties, responsiveness, and a minimally important difference were determined. External replication was performed in participants enrolled in the Severe Asthma Research Program phase 1/2. The utility of ASSESS for detecting treatment response was explored in participants undergoing corticosteroid responsiveness testing with intramuscular triamcinolone and participants receiving biologics. RESULTS: ASSESS scores ranged from 0 to 20 (8.78 ± 3.9; greater scores reflect worse severity) and differed among 5 phenotypic groups. Measurement properties were acceptable. ASSESS was responsive to changes in quality of life with a minimally important difference of 2, with good specificity for outcomes of asthma improvement and worsening but poor sensitivity. Replication analyses yielded similar results, with a 2-point decrease (improvement) associated with improvements in quality of life. Participants with a 2-point or greater decrease (improvement) in ASSESS scores also had greater improvement in lung function and asthma control after triamcinolone, but these differences were limited to phenotypic clusters 3, 4, and 5. Participants treated with biologics also had a 2-point or greater decrease (improvement) in ASSESS scores overall. CONCLUSIONS: The ASSESS tool is an objective measure that might be useful in epidemiologic and clinical research studies for quantification of treatment response in individual patients and phenotypic groups. However, validation studies are warranted.


Assuntos
Asma/tratamento farmacológico , Asma/patologia , Índice de Gravidade de Doença , Triancinolona/administração & dosagem , Adolescente , Adulto , Criança , Feminino , Humanos , Masculino
14.
Dermatol Surg ; 46(5): 685-689, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-31490300

RESUMO

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, inflammatory condition characterized by recurrent nodules, sinus tracts, comedones, and scarring. Hidradenitis suppurativa is often associated with pain and decreased quality of life. Limited clinical trial data exist regarding the management of acute HS lesions, but clinical experience and a prospective case series suggest that intralesional triamcinolone may be useful. OBJECTIVE: To compare the efficacy of intralesional triamcinolone to placebo for the treatment of HS inflammatory lesions. MATERIALS AND METHODS: This is a double-blind, randomized, placebo-controlled trial comparing intralesional triamcinolone 10 mg/mL, triamcinolone 40 mg/mL, and normal saline (NS). Thirty-two subjects at University of North Carolina Dermatology and Skin Cancer Centers were enrolled for a total of 67 lesions. Subjects reported pain scores, days to resolution, and satisfaction on a standardized survey over a 14-day period. RESULTS: When intralesional injections of triamcinolone 10 mg/mL, triamcinolone 40 mg/mL, and NS were compared, no significant difference was found for days to HS inflammatory lesion clearance, pain reduction at Day 5, or patient satisfaction. CONCLUSION: No statistically significant difference was found between varying concentrations of triamcinolone and NS for the treatment of HS lesions. Steroid injections may be less effective for the management of acute HS than typically presumed.


Assuntos
Anti-Inflamatórios/administração & dosagem , Hidradenite Supurativa/tratamento farmacológico , Triancinolona/administração & dosagem , Doença Aguda , Adulto , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Injeções Intralesionais , Masculino , Medição da Dor , Satisfação do Paciente
15.
Dermatology ; 236(1): 46-51, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31141811

RESUMO

BACKGROUND: There is little evidence on the use of intralesional triamcinolone (ILT) for managing fistulous tracts in hidradenitis suppurativa (HS). OBJECTIVE: To assess the clinical and ultrasound response to ILT for single fistulous lesions in HS patients. METHODS: A prospective open-label study was conducted to assess response to ILT (40 mg/mL) for fistulous tracts in HS. Consecutive patients (Hurley II stage exclusively) presenting to our department were recruited from August 2016 to August 2018. They received a single injection of ILT as the sole treatment. Lesions were assessed clinically and by ultrasound at baseline and 90 days. RESULTS: Of the 53 included HS patients with fistulous tracts, 36 (67.9%) were women, 30 (56.6%) were smokers, and 36 (67.9%) were obese or overweight (body mass index ≥25). Median Sartorius score was 9.0 (IQR 9.0-36.0), and median duration of the lesion treated was 6 months (IQR 3.0-12.0). Fistulous tracts were injected with 0.5 mL triamcinolone 40 mg/mL. Seven patients were lost to follow-up. At 90 days, 20 (43.5%) lesions showed clinical and ultrasound resolution, 13 (28.3%) showed only clinical resolution while persisting on ultrasound, and 13 (28.3%) persisted both clinically and on ultrasound. Mean clinical size decreased from 17.0 to 5.1 mm (p < 0.0001), while mean length on ultrasound decreased from 16.0 to 8.6 mm (p < 0.0001). LIMITATIONS: Small sample size and no control group. CONCLUSIONS: Our study suggests that ILT is beneficial for small fistulous tracts in HS.


Assuntos
Anti-Inflamatórios/administração & dosagem , Fístula Cutânea/tratamento farmacológico , Hidradenite Supurativa/tratamento farmacológico , Triancinolona/administração & dosagem , Adolescente , Adulto , Fístula Cutânea/diagnóstico por imagem , Fístula Cutânea/etiologia , Feminino , Seguimentos , Hidradenite Supurativa/complicações , Hidradenite Supurativa/diagnóstico por imagem , Humanos , Infusões Intralesionais , Masculino , Pessoa de Meia-Idade , Sobrepeso/complicações , Estudos Prospectivos , Índice de Gravidade de Doença , Ultrassonografia , Adulto Jovem
16.
Eur J Ophthalmol ; 30(5): NP29-NP31, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31155929

RESUMO

INTRODUCTION: A case of endophthalmitis after dropless cataract surgery with intravitreal Tri-Moxi associated with severe vision loss. CASE SUMMARY: An 82-year-old male developed severe vision loss in the left eye 24 days after dropless cataract surgery with intravitreal Tri-Moxi injection. Best corrected visual acuity was hand motion in the left eye. Intraocular pressure was 13, with inferior keratic precipitates, 4 + cell with 1 mm layered hypopyon, and a plaque on the posterior capsule that blocked direct exam of the posterior segment. Ultrasonography revealed extensive vitritis without retinal or choroidal detachments. CONCLUSION: Endophthalmitis resolved and vision improved after management with vitreous tap, intravitreal and fortified topical antibiotics, and subsequent prompt pars plana vitrectomy. Vitreous sample grew fluoroquinolone-resistant staphylococcus epidermidis.


Assuntos
Extração de Catarata/efeitos adversos , Farmacorresistência Bacteriana , Endoftalmite/microbiologia , Infecções Oculares Bacterianas/microbiologia , Moxifloxacina/administração & dosagem , Infecções Estafilocócicas/microbiologia , Staphylococcus epidermidis/isolamento & purificação , Triancinolona/administração & dosagem , Idoso de 80 Anos ou mais , Antibacterianos/administração & dosagem , Combinação de Medicamentos , Implantes de Medicamento , Endoftalmite/diagnóstico , Endoftalmite/tratamento farmacológico , Infecções Oculares Bacterianas/diagnóstico , Infecções Oculares Bacterianas/tratamento farmacológico , Glucocorticoides/administração & dosagem , Humanos , Injeções Intravítreas , Masculino , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/tratamento farmacológico , Combinação Tobramicina e Dexametasona/uso terapêutico , Vancomicina/uso terapêutico , Vitrectomia
19.
J Drugs Dermatol ; 18(9): 955, 2019 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-31524997

RESUMO

A 42-year-old male with skin type I and a history of rosacea and eczema presented with crusting, erythema, and pustules distributed on the left oral commissure. Angular cheilitis was diagnosed and regular petrolatum use recommended until resolution of the lesion. Eight days later, with no improvement in symptoms, fungal and bacterial cultures were performed which resulted in the growth of cutibacterium acnes, a variant of p. acnes.


Assuntos
Dermatite Perioral/tratamento farmacológico , Glucocorticoides/administração & dosagem , Granuloma/tratamento farmacológico , Adulto , Humanos , Injeções Intralesionais , Masculino , Resultado do Tratamento , Triancinolona/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...